Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Sep;8(5):298-302.
doi: 10.1200/JOP.2011.000523. Epub 2012 Jun 26.

Conflict of interest disclosure in off-label oncology clinical trials

Blair Irwin  1 , Bradford R Hirsch, Gregory P Samsa, Amy P Abernethy
Affiliations

Conflict of interest disclosure in off-label oncology clinical trials

Blair Irwin et al. J Oncol Pract. 2012 Sep.

Abstract

Purpose: We sought to determine the prevalence, reliability, and predictors of conflict of interest (COI) and funding disclosure statements for studies of anticancer targeted therapies conducted in the off-label prescribing setting.

Methods: As a part of a federally funded systematic review, manuscripts were included in the analysis if they were used to support one of 19 indications for cancer targeted therapies that were off-label but reimbursable according to compendia published in 2006 or before. Studies were categorized according to trial design, trial results, average impact factor of journals, and presence of COI and funding disclosure statements.

Results: Among the 69 included studies, prevalence of COI and funding disclosures was low, at 33% and 58% respectively; time trends showed some improvement between 2002 to 2007, but only 60% of studies had disclosures by 2007. Predictors of COI disclosure were publication in high-impact-factor journals (P < .001), large study sample size (P = .001), enrollment exclusively in the United States (P = .04), and study of the targeted therapy in combination with other agents as opposed to the study drug alone (P = .03).

Conclusion: Disclosure of potential sources of bias in COI and funding statements in studies of off-label indications for anticancer targeted therapies was low and did not increase substantially over time.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Trend in funding and COI statement in the off-label literature between 2002 and 2007. COI, conflict of interest.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med. 2006;166:1021–1026. - PubMed
    1. Gondek K, Sagnier PP, Gilchrist K, et al. Current status of patient-reported outcomes in industry-sponsored oncology clinical trials and product labels. J Clin Oncol. 2007;25:5087–5093. - PubMed
    1. Laetz T, Silberman G. Reimbursement policies constrain the practice of oncology. JAMA. 1991;266:2996–2999. - PubMed
    1. Mitka M. Off-label cancer drug compendia found outdated and incomplete. JAMA. 2009;301:1645–1646. - PubMed
    1. “Off-label” indications for oncology drug use and drug compendia: History and current status. J Oncol Pract. 2005;1:102–105. - PMC - PubMed

Publication types